Document Detail

Thalidomide and recurrent aphthous stomatitis: a follow-up study.
MedLine Citation:
PMID:  8993957     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Thalidomide is used for the symptomatic treatment of recurrent aphthous stomatitis (RAS). Some authors reported remissions, but this was not evaluated. OBJECTIVE: To evaluate the number of patients who could stop or reduce thalidomide treatment. METHODS: Twenty-five patients with RAS treated with thalidomide and followed during at least 1 year were retrospectively studied. RESULTS: Six patients could stop the treatment and further presented minor aphthae, 10 needed minimal daily doses of thalidomide and 7 did not respond to 100 mg daily. One patient was not evaluated because of an early side effect and one was lost to follow-up. CONCLUSION: This study showed that a minority of patients responded and could stop thalidomide therapy whereas another group of patients could be maintained in remission with low doses of thalidomide which may represent a means to reduce the potentially severe side effects.
J M Bonnetblanc; C Royer; C Bedane
Related Documents :
15389187 - Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomiz...
23579357 - Rotational osteotomy with submuscular plating in skeletally immature patients with cere...
23635587 - The impact of perioperative glutamine-supplemented parenteral nutrition on outcomes of ...
20838947 - An observational study of patient-rated outcome after atlantoaxial fusion in patients w...
9220477 - Urodynamically controlled management of spinal cord injury in children.
8426317 - Keratometric comparison of 4.0 mm and 5.5 mm scleral tunnel cataract incisions.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  193     ISSN:  1018-8665     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  1996  
Date Detail:
Created Date:  1997-03-26     Completed Date:  1997-03-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  321-3     Citation Subset:  IM; X    
Department of Dermatology, CHRU Dupuytren, Limoges, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dose-Response Relationship, Drug
Evaluation Studies as Topic
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Retrospective Studies
Stomatitis, Aphthous / diagnosis,  drug therapy*,  physiopathology
Thalidomide / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Immunosuppressive Agents; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Homoeopathic versus placebo therapy of children with warts on the hands: a randomized, double-blind ...
Next Document:  Double-blind crossover study of high-dose cetirizine in cholinergic urticaria.